Half of the participants now dosed in Dicot Pharma's Phase 2a study

Uppsala, Sweden, February 5, 2025. The recruitment rate in the potency drug developer Dicot Pharma's ongoing phase 2a study is high and in alignment with the planned timeline, where the study is expected to be reported in mid-2025. Today, half of the 140 participants have been dosed.

Today, Dicot Pharma announces that the recruitment of participants for the company's clinical phase 2a study is advancing at a steady rate, and that half of the planned 140 participants have now been dosed.

"We set an ambitious recruitment plan, and thanks to the efficient work of our clinical partners and high level of interest in participating in the study, we have managed to maintain a high recruitment rate," says Charlotta Gauffin, CSO at Dicot Pharma.

All participating men have erectile dysfunction and have been in a stable relationship for at least six months. To evaluate the effect of LIB-01 on erectile function, they respond to questions from the standardized questionnaire International Index of Erectile Function. In addition, participants continuously fill out a form of diary after each sexual intercourse.

About the phase 2a study
The purpose of the Phase 2a study is to evaluate the efficacy of LIB-01 in men with erectile dysfunction. The study is expected to include 140 participants and is being conducted at six clinics in Sweden (Uppsala, Stockholm, Gothenburg and Linköping), Denmark (Herlev) and the Netherlands (Groningen). Each person will participate in the study for eight weeks after dosing. The trial is double blind and placebo controlled. This means that neither the clinical staff administering the study drug, nor the participants, know which research subjects are receiving LIB-01 and which are receiving placebo. The clinical part of the study is expected to last until mid-2025. This will be followed by a statistical analysis before the results can be reported.

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance

and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 8,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.